KRYSTAL BIOTECH DL-,00001

At the Cantor conference Krystal Biotech presented a scalable herpes‑simplex vector platform and emphasized that the company has reported positive EPS for three years and does not expect to need external funding for the pipeline. US sales for VYJUVEK have settled at about $85–95 million per quarter; international growth in Europe and Japan is expected to be the next driver within the next 12–18 months but faces pricing pressure and MFN uncertainties. Several clinical readouts (Hailey‑Hailey disease, ocular programs, lung cancer) are upcoming and could materially change the company’s profile. » Mere på de.investing.com

Krystal Biotech’s stock rose to an all-time high of around $316.53, giving it a market capitalization of about $9.25 billion. Over the past year the stock gained 138.49%; InvestingPro currently rates it as slightly overvalued. Krystal reported a strong first quarter with earnings per share of $1.83 (expectation $1.48) and revenue of $116.4 million, beating both BofA and consensus estimates; BofA nonetheless marginally cut its price target from $325 to $323 and confirmed its buy recommendation. » Mere på de.investing.com

Krystal Biotech reported Q1 2026 EPS of $1.83 (estimate $1.48) and revenue of $116.4 million, with both metrics beating expectations. Net income rose 56.6% to $55.9 million and gross margin improved to 95%. The stock fell about 2.3% in premarket trading despite the results. For Q2 and Q3 2026 the company guides to EPS of $1.86 and $2.21 and revenues of $126.45 million and $142.5 million, but cites risks from price negotiations in Europe, higher operating costs and potential market saturation in the US. » Mere på de.investing.com

Krystal Biotech has turned profitable and grew 2025 revenue 34% to $389.1 million, driven by Vyjuvek, the first FDA-approved therapy for dystrophic epidermolysis bullosa. The company targets modest patient populations in the U.S., Japan and parts of Europe and is developing additional gene-therapy candidates including KB407 and KB408. Sustaining multidecade, life-changing returns would require successful launches of these pipeline drugs and protection of pricing power amid potential competition and clinical or regulatory risks. » Mere på finance.yahoo.com

At the TD Cowen healthcare conference, Krystal Biotech presented plans to boost VYJUVEK revenue through at-home self-administration, expanding the U.S. sales force and international expansion, with particular focus on Germany, Italy, France and Japan. The company is increasing dosing frequency in its ophthalmology programs to improve adherence and plans to resume KB803 phase 3 recruitment with top-line data expected by year-end. For the CF program, Krystal reported promising molecular correction data and positive regulatory feedback from the FDA, CFF and TDN; KB111 is being prioritized due to prospects for rapid approval. The company cited risks including price negotiations in Europe and potential uncertainties in approval and trial processes. » Mere på de.investing.com